Thin melanomas with partial or complete regression may provide clues about antitumor immunity, but their management remains controversial. We have characterized the management and clinical outcomes of regressed thin (< 1 mm) T1a melanomas and hypothesized that regression increases the risk of regional metastases when compared with nonregressed thin melanomas. A prospectively collected clinical database was reviewed, and T1a melanomas with regression were identified. Histology, surgical approach, outcome, and survival were evaluated. The primary outcome measures were sentinel node positivity, subsequent lymph node metastasis, and survival. A total of 75 patients with T1a or in-situ melanomas were grouped into three subsets. Group 1: 35 underwent a sentinel node biopsy (SNBx), none of which were positive. No patients developed nodal recurrence. The 5-year survival of this group was 93%, with a median follow-up of 52 months. Group 2: 31 were followed up without SNBx; two developed regional nodal disease (6.5%), neither of whom died of subsequent distant disease. The 5-year survival was 89%, with a median follow-up of 38 months. There was no significant difference in the survival between groups 1 and 2. Group 3: nine patients presented with metastatic disease concurrent with a regressed thin melanoma. These patients had a median survival of 2.3 years and a 4-year survival estimate of 22%. Regression should not be used as an indication for SNBx in T1a melanomas; we recommend that such patients be managed with wide local excision and a long-term clinical follow-up. The poor prognosis of thin regressed primary melanoma with simultaneous metastatic disease may indicate the existence of immune escape phenotypes supporting melanoma progression.
Introduction
Spontaneous regressions of malignant melanoma have been described for decades, including isolated partial or complete regressions of cutaneous lesions and complete and durable regressions of systemic metastatic disease [1] [2] [3] [4] [5] [6] [7] [8] . These regressions are commonly attributed to immunologic events, although the biology remains incompletely characterized [9] . Patients with thin melanomas [American Joint Committee on Cancer staging (AJCC) stage IA] have a good prognosis [10] , but a minority of patients with thin melanomas develops metastases, and some die of metastatic melanoma. In some studies, histologic evidence of regression has had a negative prognostic impact [4, [11] [12] [13] [14] [15] [16] , whereas in other studies, regression did not have independent negative prognostic significance [17] [18] [19] [20] [21] [22] [23] [24] . Because of these discordant data on the prognostic significance of regression in thin malignant melanomas, there are no standard guidelines for performing a sentinel node biopsy (SNBx) for thin lesions with regression.
On the basis of the previous experience of one author (C.L.S.) that melanoma with severe regression is associated with a higher risk of recurrence [13] , our practice has been to offer SNBx to patients with histologic evidence of partial or complete regression in thin melanomas and clinically negative nodes. In this study, we identify a subset of patients with thin melanoma and histologic evidence of regression. By determining the rate of SNBx positivity, and evaluating the patterns of recurrence and metastasis, we aim to understand whether regression is a prognostic indicator for sentinel node positivity. We hypothesize that patients with thin melanomas showing regression would have an increased likelihood of sentinel lymph node positivity and increased rates of local and distant recurrence as compared with published rates of thin melanomas. We have also observed a different clinical presentation of regression, in which patients present with clinical evidence of metastatic melanoma concurrent with the diagnosis of a partially or completely regressed primary lesion [25] . Our secondary aim is to understand the difference in the biology of patients who present with regression and thin melanoma only as compared with patients who present with regression concurrent with distant disease. prospectively collected database and identified patients diagnosed with thin (< 1 mm) malignant melanoma, including melanoma in situ, at a single institution. Patients were excluded if they had other adverse prognostic factors considered to be indications for SNBx, including a Clark level greater than 3, a positive deep margin on initial biopsy, microscopic satellites, and ulceration. Histologic data collected for this study included regression, ulceration, Breslow depth, Clark's level, growth phase, microscopic satellites, and the radial or vertical growth pattern of the primary melanoma. Information on the surgical management of the primary lesion and nodes, as well as outcomes including recurrence, metastasis, and survival was also collected. Subsequent review of individual charts, as well as the Social Security Death Index, provided additional details.
The pathology slides of all patients who fulfilled the inclusion criteria were evaluated by a dermatopathologist (J.W.P.), and they were considered to have histologic evidence for regression on the basis of the following criteria: dermal fibroplasia, pigmentary incontinence, vascular proliferation, and lymphocytic infiltrate [26] . In addition, there was often effacement of the overlying rete ridge pattern. Inflammatory infiltrates alone were not considered to be regression for the purposes of this study. The extent of regression was not formally quantified but was described in several categories on the basis of radial extent: complete (defined as the absence of residual melanoma cells in the presence of dermal fibroplasia, vasodilatation, perivascular inflammation, and/or dermal pigment deposition), partial (defined as extensive, significant, or marked areas of the specimen with fibrosis, inflammation, and/or pigmentary incontinence), or focal (defined as zones or areas of fibrosis, inflammatory infiltrate, and/or pigmentary incontinence) [27] . In addition, previously established criteria for completely regressed melanoma with lymph node metastases were used as a basis for defining the extent of regression in such patients [26] . The clinical criteria for the diagnosis of complete regression are presented in Table 1 . Patients referred after the development of metastasis represent a subset of patients with an unknown denominator; thus, this paper excludes patients referred for the management of metastasis after the diagnosis of a thin melanoma elsewhere.
All patients in this series were treated with a wide local excision with a 1-cm margin. The draining nodal basin was addressed in a varied manner during the period studied. We began recommending SNBx in 1995, and thus patients treated before 1995 were not offered SNBx. From 1995 through the time period reported in this paper, our recommendation for performing an SNBx in patients with melanomas at least 1 mm in thickness was based on the following criteria: T1b (Clark's level 4 or greater, or ulceration) or a positive deep margin at biopsy. These melanomas were not included in this study. In addition, from 1995 to 2006, we also recommended SNBx for thin melanomas with severe regression. We also performed some SNBx for thin melanomas solely upon patient request. In addition, there were some patients who fulfilled the criteria for sentinel lymph node biopsy (SLN Bx) but did not undergo the procedure because of overall health status or patient preference.
Patients who fulfilled the inclusion criteria were divided into three groups for analysis: (i) those managed with SNBx, (ii) those followed up clinically without the surgical management of the draining nodes, and (iii) those who presented with metastatic disease synchronous with the diagnosis of a regressed melanoma. The outcomes in patients of groups 1 and 2 were compared with the outcomes reported for those patients with AJCC stage IA melanoma without regression [28, 29] .
Pearson's w 2 -test was used to compare categorical data and analysis of variance was used to compare continuous data. Kaplan-Meier survival functions were calculated for disease-free and overall survival. The log Rank Mantel-Cox test was used to assess statistical significance. P-values of less than 0.05 were considered significant. To estimate an upper bound for the rate of positive SNBx, a one-sided exact binomial confidence interval was calculated. Statistical analyses were performed using SAS 9.1 and SPSS version 17.0 (SPSS Inc., Chicago, Illinois, USA).
Results
We identified 1505 patients treated for malignant melanoma at a single institution between 1991 and 2006. This included 275 patients with thin primary melanomas, of whom 75 were included in this study. These 75 were patients with thin melanoma and regression without other indications for SNBx (Clark's level 4 or 5, positive deep margin on biopsy, microscopic satellites, ulceration, and no clinical evidence of metastases at presentation). These patients included 35 patients managed with SNBx (group 1) and 31 patients managed with the clinical evaluation of nodes only (group 2). These groups form the basis for evaluation of the impact of regression on SNBx and recurrence in this study. In addition, we identified nine patients presenting with clinical evidence of metastatic melanoma concurrent Table 1 Criteria for diagnosing complete regression of primary cutaneous melanoma a 1. Metastatic melanoma to regional nodes draining the site of the presumed regressed primary lesion or to one or more distant sites 2. Absence of any other primary lesion identifiable by history or physical examination that could represent the original primary melanoma 3. Presence of an atypical pigmented or depigmented change in the skin at the site of the presumed primary lesion, with all or a majority of the typical histologic features associated with regression found on biopsy (attenuated epidermis, dermal melanophages, lymphocytic or chronic inflammatory infiltrate, reactive vascular proliferation, and fibrosis with the diagnosis of a partially or a completely regressed primary lesion (group 3).
Demographics
Overall, 65% of the patients were men ( Table 2 ). Group 1 included 71% men, group 2 included 52% men, and group 3 included 89% men (P = 0.07). The mean age was 53 years for group 1, 54 years for group 2 (range: 19-73), and 50 years for group 3 (range: 31-82; P = 0.78). Overall, the majority of lesions were found on the trunk (51%). In groups 1 and 2, 54 and 48% of the patients had trunk primaries, respectively, whereas 40 and 48% had extremity primaries. A significantly higher proportion of patients in group 3 (three of nine or 33%) had head and neck primaries (P = 0.046; Table 2 ).
Histologic information
The histologic subtype was similar in groups 1 and 2. Superficial spreading melanoma was the most common (31%), followed by melanoma in situ and the lentiginous subtype ( Table 3 ). The majority of melanoma in situ was further subtyped histologically, and the most common subtype identified was lentiginous (five patients). A total of 39% of the patients had no listed histologic subtype. Partial regression was the most common pattern found in groups 1 and 2 ( Table 3 ). As expected, group 3 had significantly more lesions with complete regression (P = 0.008). Clark level 3 was the most common level in both groups 1 and 2, at 40 and 48%, respectively. Clark level data in group 3 were insufficient for analysis. In total, 26 patients had radial growth phase lesions and 17 had vertical growth phase lesions. There was no difference between groups 1 and 2 with respect to the growth phase (P = 0.39). Group 3 had insufficient data for analysis.
In group 3, the primary lesions were either diagnosed within 3 weeks before the identification of metastatic disease or within 4 months after the identification of metastatic disease. The majority (eight) presented with lymph node metastasis, and a regressed melanoma was subsequently identified in an area expected to drain into the tumor-involved node(s). The other patient presented with a brain metastasis that was resected and found to be a melanoma, and a completely regressed primary lesion was subsequently identified.
Surgical management
Among all patients, full-thickness excisional biopsies were the most common, performed in 71% of the patients. In total, 11% of patients underwent a shave biopsy and 20% of patients did not have biopsy information available. A total of 33 patients (44%) underwent complete removal of the lesion with initial biopsy. Of the patients, 19% had residual melanoma in the wide local excision specimen. Six patients (11%) elected not to undergo wide local excision, four of whom had concurrent distant metastases and were included in group 3.
Group 1 patients underwent SNBx, and none had a positive SNBx (0%; 0/35, 95% upper bound 8.2%). Although seven patients showed evidence for vertical growth phase lesions, this factor was not associated with sentinel node positivity. Group 2 patients did not undergo SNBx, and were instead followed up through physical examination and annual complete blood count and chest radiographs ( Table 4 ). The eight group 3 patients with regional nodal disease at diagnosis underwent a diagnostic biopsy (fine needle aspiration or incisional), followed by a complete nodal dissection. Seven of these patients had one or two positive nodes in their completion dissection and one patient had 16 of 19 positive lymph nodes.
Outcomes

Group 1
The median follow-up was 52 months. Two patients (5.5%) developed recurrence. One had local recurrence 19 months after original diagnosis, underwent re-excision, and is alive, with no evidence of disease 48 months following re-excision. The other patient had distant recurrence 56 months after original diagnosis and died of progressive disease. Notably, no patients had nodal recurrence. The 5-year survival was 93% [standard error (SE) 6%; Fig. 1 ].
Group 2
The median follow-up was 38 months. Four patients (11.8%) developed recurrence. Two patients (6.5%) developed regional nodal recurrence: one at 10 years and one at 21 years. Both had lymphadenectomies and both remain alive and clinically free of disease 6.26 and 7.7 years after the surgical management of their lymph node metastases. Two other patients developed distant metastatic disease: one with subcutaneous metastases, who is alive with disease, and one with multiple distant visceral metastases, who died of progressive disease ( Table 4 ). The 5-year survival was 89% (SE 7%; Fig. 1 ).
Group 3
Six patients (67%) developed further progression of the disease. These six patients died, one of whom died of Combining groups 1 and 2, the overall recurrence rate was 9.1% and the nodal recurrence rate was 3.0%. The 5-and 10-year overall survival rates were 92% (SE 4%) and 87% (SE 6%). There was no significant difference in the survival between groups 1 and 2. Survival is comparable with the reported 5-year survival estimates for patients with AJCC stage IA disease (95.3%±0.4) [29] . When all patients are combined, the overall 5-year survival is 80% (SE 6%).
Discussion
The prognostic significance of regression in thin melanoma is poorly defined. Our data have provided an insight into two presentations of melanoma with regression, which have distinct clinical outcomes. Type 1 regression patients are those with thin melanomas and regression who do not show clinical evidence for metastatic disease on presentation. Within this group, we have evaluated the role of SNBx performance and its prognostic implications. Type 2 regression patients are those who present with metastatic melanoma and in whom a regressed primary melanoma was concurrently or subsequently discovered on physical examination. The differences in the outcomes for these two groups raise the possibility of differing mechanisms of tumor development, suggesting further potential for immunologic inquiry and study.
The selection of patients with thin melanomas for SNBx remains an area of debate, without consistent findings among multiple studies (Table 5 ) [11, 13, 16, [22] [23] [24] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] .
Previous studies have suggested that regression is associated with a poor prognosis. Several studies have associated regression with a higher risk of metastasis to lymph nodes [11, 44] . Clark et al. [15] included regression as a poor prognostic indicator in their model predicting survival in stage I melanoma. Blessing et al. [16] studied a group of patients who had experienced metastatic disease or died of melanoma and found that, compared with controls, the patients with poor outcomes were more likely to have had regression of their tumor.
In a study of prognostic factors in thin melanoma, Slingluff et al. found that the presence of severe regression reduced the disease-free interval compared with that in similar lesions without regression [13] . We now believe that the negative associations of regression are explained by the inclusion of a patient population such as that in group 3 in this study (synchronous with the diagnosis of distant metastases). These patients have survival outcomes that are much worse than those in patients with thin melanomas and type 1 regression.
More recent studies investigating the use of SNBx in the setting of regression have concluded that regression is not an indication for SNBx in the setting of thin melanoma [22] [23] [24] 45] . Morris et al. [22] evaluated 344 patients with regression in their primary melanoma and found a consistently lower incidence of positive SNBx as compared with that in primary melanomas without regression at all Breslow depths. Cecchi et al. [23] retrospectively evaluated 59 patients with thin melanoma and found no correlation between the presence of regression and the outcome of SNBx. Two studies found a lower incidence of SLN positivity in patients with regression than in patients without regression and concluded that regression is not an independent risk factor for SLN metastasis Kaplan-Meier survival curve of patients managed without a sentinel node biopsy (dotted line) versus patients managed with a sentinel node biopsy (solid line) versus patients with metastasis at diagnosis (dashed line). [24, 46] . The present study agrees that regression is not an unfavorable prognostic factor and advocates that thin melanomas with regression and no other negative prognostic factor do not require SNBx.
For those patients with thin melanomas and type 1 regression, SNBx has routinely been performed at this institution. In the present study, 3% of patients (2/66) with T1a melanomas with regression had clinically or histologically evident metastases to regional nodes. This is comparable with the sentinel node positivity rate for all T1 melanomas and the regional nodal metastasis rate of T1a patients not undergoing SNBx [13, [37] [38] [39] 47, 48] . Thus, type 1 regression in thin melanomas does not appear to be associated with an increased risk for nodal metastasis. On the basis of these data, we no longer recommend SNBx for patients with T1a melanomas solely on the basis of histologic evidence of regression. It is appropriate, however, for these patients to be followed up regularly for at least 20 years after the excision of their primary tumor, maintaining high vigilance for clinically detectable metastases.
It is possible that patients with occult lymph nodes may not present with clinically evident metastases for a decade or more after the diagnosis and excision of a thin melanoma; hence, the incidence of regional node metastasis observed in patients managed only with wide local excision may slightly underestimate the actual risk of nodal metastases. Similarly, histological evaluation of sentinel nodes may miss a few clinically significant micrometastases or may identify very small metastases that will not evolve into clinically evident disease. Thus, assessment of the risk of lymph node metastasis by either SNBx or observation may be considered as inaccurate. However, the very low rates of regional recurrence in both groups 1 and 2 support the general conclusion that regression of a primary melanoma is associated with low rates of regional node metastasis.
The conflicting data and opinions on the significance of regression may be related to the difficulty in the identification and categorization of regression in a histological study. Recent studies have reported markedly different rates of regression (23-70%), perhaps indicating that there is a lack of consensus in the definition of regression [22] [23] [24] . Requena et al. [49] advocate dividing regression into two phases: an early 'regressing' phase (which is primarily inflammatory) and a late 'regressed' phase (primarily scarring). Because any lesion showing melanoma with early regression will be resected, it is impossible to know whether 'regressing' melanoma progresses inexorably to 'regressed' melanoma. This raises the possibility that early and late regression may be biologically distinct entities with distinct prognostic values. Combining these two phases into a single category may account for the disparity among studies.
The exact biological nature of regression is poorly understood, and some believe that it is immune mediated [8, 50] . It is believed that progressive inflammation within the tumor induces the destruction of malignant cells, causing fibrous tissue to underlie or replace malignant cells [51] . Stimulation by tumorassociated antigens initiates a cell-mediated immune response, ultimately causing the destruction of tumor cells by cytotoxic CD8 + lymphocytes [51] [52] [53] . In theory, this immune response would represent a favorable prognostic indicator. A fascinating theory is that lymph node metastases are a prerequisite for regression of the primary melanoma [33] . Shaw and colleagues identified 28 patients with thin melanomas (< 0.76 mm), who presented with simultaneous clinically detectable lymph node metastasis. All 28 of these patients had primary lesions that showed histological evidence of regression (defined as 'early', 'intermediate', and 'late'), with all except two showing evidence for late regression [54] . They hypothesized that the regional spread of the melanoma to lymph nodes increased the immune response against the primary melanoma by increasing the activity of cytotoxic T cells at the primary site while activating suppressor T cells within the lymph node itself (thus explaining why the lymph node metastases evade destruction) [54] .
We suspect that immune responses occur in regional nodes for most or all patients with regressed melanomas and that patients in groups 1 and 2 have had successful eradication both of the primary lesion and of any metastases to the nodes, whereas those in group 3 have tumor cells in the nodes that escape immune recognition and progress while the primary lesion is controlled by the immune response generated in the nodes. Further characterization of the specificity of the T-cell response in nodes and at the primary site is needed to test or to modify this hypothesis. Immunologic studies of lymphocytes in regressed primaries may help identify factors that predispose patients to allow tumor escape. In their review of tumor escape, Poggi and Zocchi suggest that immunoselective pressure can favor tumor cells that have become resistant through loss of human leukocyte antigen alleles and have evaded the immune response [55] . If this were the case, it is possible that the immune response leading to regression could paradoxically increase the malignant potential of the tumor in certain cases.
Limitations of study
This study's retrospective nature and the small sample size can be identified as limitations. In addition, the tertiary referral center that sees a high volume of metastatic or high-risk patients lends a patient selection bias toward patients with thin melanomas who have metastatic disease and a less favorable prognosis. This has been resolved through the inclusion of only patients who received treatment for their primary melanoma at our institution. Considering that this study focuses on a specific subset of thin regressed melanomas without other negative prognostic factors (Clark level > 3, ulceration, or positive deep margin), it can be concluded that thin melanomas with regression do not have an increased likelihood of sentinel node positivity or distant metastases, and regression alone should not be a determinant in the selection for sentinel node evaluation.
Conclusion
The current review has helped us to clarify the presentation, natural history, and appropriate management of T1 melanomas with regression and suggests avenues for future research to characterize the tumor biology and immunobiology that explain the differences in these two presentations.
